The risk of venous thromboembolism (VTE) in the oncology population is significantly higher than in non-cancer patients. Inferior vena cava (IVC) filters may, therefore, be an important part of VTE treatment. In this study, we address the outcomes of placing IVC filters in the oncology population. This single-centre, observational, retrospective study included 62 patients with active malignancy and acute VTE who underwent an IVC filter implantation due to contraindications to anticoagulation during the period 2012–2023. The control group consisted of 117 trauma patients. In both groups, an urgent surgical procedure requiring temporary cessation of anticoagulation was the most noted reason for IVC filter placement—76% in the oncology group vs. 100% in the non-oncology group (p< 0.001). No complications were reported during the IVC filter implantation procedures. There was no recurrence of pulmonary embolism or deep venous thrombosis in the oncology group after filter implantation. The rate of successful filter explantation, median time to retrieval, and abnormal findings during retrieval were not significantly different between both subgroups (64.3% vs. 76.5%,p= 0.334; 77 days vs. 84 days,p= 0.764; 61.5% vs. 54.2%,p= 0.672; respectively). The study showed that IVC filter placement is a safe and effective method of preventing PE in cancer patients with contraindications to anticoagulation. The complication rate following IVC filter implantation in cancer patients is low and similar to that in non-oncology patients.
肿瘤患者发生静脉血栓栓塞症的风险显著高于非癌症患者。因此，下腔静脉滤器可能成为静脉血栓栓塞症治疗的重要组成部分。本研究旨在探讨肿瘤患者植入下腔静脉滤器的临床结局。这项单中心观察性回顾研究纳入了2012年至2023年间62例活动性恶性肿瘤合并急性静脉血栓栓塞症患者，因存在抗凝禁忌而接受下腔静脉滤器植入。对照组为117例创伤患者。两组中，因需紧急手术而需暂时中断抗凝治疗是下腔静脉滤器植入最主要的原因——肿瘤组占76%，非肿瘤组为100%（p<0.001）。滤器植入过程中均未报告并发症。肿瘤组患者在滤器植入后未出现肺栓塞或深静脉血栓复发。两组在滤器成功取出率、中位取出时间及取出时异常发现方面均无显著差异（分别为64.3%对比76.5%，p=0.334；77天对比84天，p=0.764；61.5%对比54.2%，p=0.672）。研究表明，对于存在抗凝禁忌的癌症患者，下腔静脉滤器植入是预防肺栓塞安全有效的方法。癌症患者植入下腔静脉滤器后的并发症发生率较低，与非癌症患者相似。
肿瘤(癌症)患者之家